Purnanand Sarma, Ph.D., President & CEO of Immunome Inc, said, “IMM-BCP-01’s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19. We believe our lead candidate’s mechanism of action, targeting at least three non-overlapping epitopes – informed by the authentic human immune response – provides a robust defense against future mutational drift. Currently, the delta variant accounts for a majority of coronavirus cases in the United States.”

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.

About Immunome Inc

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.

Immunome has been granted a $17.6 million technology award from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

For more information, please visit the Company’s website at: www.immunome.com.

Immunome Inc Stock

Prohost Observations

As promised, we decided to follow up on this firms plans.

********************

Following Up on Cytokinetics’ Stock Surge 

Yesterday, we posted news under Today’s Highlights about Cytokinetics’ (CYTK) stock soaring following the firm’s announcement of positive topline results of Phase 2 clinical trial of (CK-274) – an investigational cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

The results informed dose selection, supporting the progression of CK-274 to the planned Phase 3 registrational clinical trial expected to start before year-end.

Today, the stock continued to outperform, trading early at around $29.86, UP $2.86.

Click here to read more about Immunome.

Click here to read more about Cytokinetics.